NUF2与肿瘤预后

国际肿瘤学杂志››2022,Vol. 49››Issue (3): 164-167.doi:10.3760/cma.j.cn371439-20211025-00027

任梦¹, 杨璐², 赵晓婷¹, 岳文涛¹()

¹首都医科大学附属北京妇产医院北京妇幼保健院中心实验室,北京 100026
²北京亦庄国际蛋白药物技术有限公司,北京 100023

收稿日期:2021-10-25修回日期:2021-11-10出版日期:2022-03-08发布日期:2022-03-22
通讯作者:岳文涛 E-mail:yuewt@ccmu.edu.cn
基金资助:
北京市科技计划(Z181100001718193)

NUF2 and tumor prognosis

Ren Meng¹, Yang Lu², Zhao Xiaoting¹, Yue Wentao¹()

¹Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
²Beijing Etinpro Technologies Co.Ltd, Beijing 100023, China

Received:2021-10-25Revised:2021-11-10Online:2022-03-08Published:2022-03-22
Contact:Yue Wentao E-mail:yuewt@ccmu.edu.cn
Supported by:
Science & Technology Commission of Beijing Municipal of China(Z181100001718193)

摘要/Abstract

摘要：

NUF2负责动粒-微管的附着,在细胞有丝分裂期间姐妹染色单体的正确分离中起关键作用。NUF2在肝细胞癌、胰腺癌、食管癌、非小细胞肺癌、乳腺癌等多种肿瘤组织及细胞中高表达,可作为预后评估的有效标志物。进一步阐述NUF2与肿瘤预后的关系,将为NUF2应用于临床肿瘤预后判断提供帮助。

任梦, 杨璐, 赵晓婷, 岳文涛. NUF2与肿瘤预后[J]. 国际肿瘤学杂志, 2022, 49(3): 164-167.

Ren Meng, Yang Lu, Zhao Xiaoting, Yue Wentao. NUF2 and tumor prognosis[J]. Journal of International Oncology, 2022, 49(3): 164-167.

参考文献27

[1]	Ustinov NB, Korshunova AV, Gudimchuk NB. Protein complex NDC80: properties, functions, and possible role in pathophysiology of cell division[J]. Biochemistry (Mosc), 2020, 85(4):448-462. DOI: 10.1134/S0006297920040057. doi:10.1134/S0006297920040057
[2]	Subramonian D, Chen TA, Paolini N, et al. Poly-SUMO-2/3 chain modification of Nuf2 facilitates CENP-E kinetochore localization and chromosome congression during mitosis[J]. Cell Cycle, 2021, 20(9):855-873. DOI: 10.1080/15384101.2021.1907509. doi:10.1080/15384101.2021.1907509
[3]	Uehara DT, Mitsubuchi H, Inazawa J. A missense variant in NUF2, a component of the kinetochore NDC80 complex, causes impaired chromosome segregation and aneuploidy associated with microcephaly and short stature[J]. Hum Genet, 2021, 140(7):1047-1060. DOI: 10.1007/s00439-021-02273-4. doi:10.1007/s00439-021-02273-4
[4]	魏永健, 胡进静, 李汛. CDCA8与肿瘤发生发展及干细胞干性维持的关系[J]. 国际肿瘤学杂志, 2021, 48(4):216-219. DOI: 10.3760/cma.j.cn371439-20201012-00043. doi:10.3760/cma.j.cn371439-20201012-00043
[5]	Jiang X, Jiang Y, Luo S, et al. Correlation of NUF2 overexpression with poorer patient survival in multiple cancers[J]. Cancer Res Treat, 2021, 53(4):944-961. DOI: 10.4143/crt.2020.466. doi:10.4143/crt.2020.466
[6]	Lv S, Xu W, Zhang Y, et al. NUF2 as an anticancer therapeutic target and prognostic factor in breast cancer[J]. Int J Oncol, 2020, 57(6):1358-1367. DOI: 10.3892/ijo.2020.5141. doi:10.3892/ijo.2020.5141
[7]	Wang Y, Tan PY, Handoko YA, et al. NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection[J]. Int J Cancer, 2019, 145(3):662-670. DOI: 10.1002/ijc.32134. doi:10.1002/ijc.32134pmid:30653265
[8]	Guo L, Wang Z, Du Y, et al. Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma[J]. Cancer Cell Int, 2020, 20:251. DOI: 10.1186/s12935-020-01274-z. doi:10.1186/s12935-020-01274-z
[9]	Jacobs NR, Norton PA. Role of chromosome 1q copy number variation in hepatocellular carcinoma[J]. World J Hepatol, 2021, 13(6):662-672. DOI: 10.4254/wjh.v13.i6.662. doi:10.4254/wjh.v13.i6.662
[10]	Zhang Y, Tang Y, Guo C, et al. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(9):12865-12895. DOI: 10.18632/aging.202957. doi:10.18632/aging.202957
[11]	Xie X, Jiang S, Li X. Nuf2 is a prognostic-related biomarker and correlated with immune infiltrates in hepatocellular carcinoma[J]. Front Oncol, 2021, 11:621373. DOI: 10.3389/fonc.2021.621373. doi:10.3389/fonc.2021.621373
[12]	Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets[J]. Cancer Cell, 2019, 35(4): 588-602. e10. DOI: 10.1016/j.ccell.2019.02.009. doi:S1535-6108(19)30104-7pmid:30930117
[13]	Xing C, Wang Z, Zhu Y, et al. Integrate analysis of the promote function of cell division cycle-associated protein family to pancreatic adenocarcinoma[J]. Int J Med Sci, 2021, 18(3):672-684. DOI: 10.7150/ijms.53243. doi:10.7150/ijms.53243
[14]	Wong CH, Lou UK, Li Y, et al. CircFOXK2 promotes growth and metastasis of pancreatic ductal adenocarcinoma by complexing with RNA-binding proteins and sponging miR-942[J]. Cancer Res, 2020, 80(11):2138-2149. DOI: 10.1158/0008-5472.CAN-19-3268. doi:10.1158/0008-5472.CAN-19-3268pmid:32217695
[15]	Zheng L, Li L, Xie J, et al. Six novel biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma: validated by scRNA-seq and qPCR[J]. J Cancer, 2021, 12(3):899-911. DOI: 10.7150/jca.50443. doi:10.7150/jca.50443
[16]	Chen M, Li S, Liang Y, et al. Integrative multi-omics analysis of identified NUF2 as a candidate oncogene correlates with poor prognosis and immune infiltration in non-small cell lung cancer[J]. Front Oncol, 2021, 11:656509. DOI: 10.3389/fonc.2021.656509. doi:10.3389/fonc.2021.656509
[17]	Sun ZY, Wang W, Gao H, et al. Potential therapeutic targets of the nuclear division cycle 80 (NDC80) complexes genes in lung adenocarcinoma[J]. J Cancer, 2020, 11(10):2921-2934. DOI: 10.7150/jca.41834. doi:10.7150/jca.41834
[18]	Hitti E, Bakheet T, Al-Souhibani N, et al. Systematic analysis of AU-Rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins[J]. Cancer Res, 2016, 76(14):4068-4080. DOI: 10.1158/0008-5472.CAN-15-3110. doi:10.1158/0008-5472.CAN-15-3110
[19]	Xu W, Wang Y, Wang Y, et al. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer[J]. Int J Mol Med, 2019, 44(2):390-404. DOI: 10.3892/ijmm.2019.4239. doi:10.3892/ijmm.2019.4239
[20]	Zhai X, Yang Z, Liu X, et al. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer[J]. PeerJ, 2020, 8:e9975. DOI: 10.7717/peerj.9975. doi:10.7717/peerj.9975
[21]	Zhang W, Qiu X, Sun D, et al. Systematic analysis of the clinical relevance of cell division cycle associated family in endometrial carcinoma[J]. J Cancer, 2020, 11(19):5588-5600. DOI: 10.7150/jca.46324. doi:10.7150/jca.46324
[22]	Tang H, Wu Z, Zhang Y, et al. Identification and function analysis of a five-long noncoding RNA prognostic signature for endometrial cancer patients[J]. DNA Cell Biol, 2019, 38(12):1480-1498. DOI: 10.1089/dna.2019.4944. doi:10.1089/dna.2019.4944
[23]	Xie X, Lin J, Fan X, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription[J]. Cell Death Dis, 2021, 12(2):201. DOI: 10.1038/s41419-021-03489-y. doi:10.1038/s41419-021-03489-y
[24]	Zhang H, Zou J, Yin Y, et al. Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma[J]. PeerJ, 2019, 7:e8096. DOI: 10.7717/peerj.8096. doi:10.7717/peerj.8096
[25]	Shan L, Zhu XL, Zhang Y, et al. Expression and clinical significance of NUF2 in kidney renal clear cell carcinoma[J]. Transl Androl Urol, 2021, 10(9):3628-3637. DOI: 10.21037/tau-21-620. doi:10.21037/tau-21-620pmid:34733658
[26]	Tokuzumi A, Fukushima S, Miyashita A, et al. Cell division cycle-associated protein 1 as a new melanoma-associated antigen[J]. J Dermatol, 2016, 43(12):1399-1405. DOI: 10.1111/1346-8138.13436. doi:10.1111/1346-8138.13436
[27]	Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma[J]. Cancer Cell, 2021, 39(3): 361-379. e16. DOI: 10.1016/j.ccell.2020.12.007. doi:10.1016/j.ccell.2020.12.007pmid:33417831

NUF2与肿瘤预后

NUF2 and tumor prognosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献27

相关文章15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.